Progress in Neuro-Psychopharmacology & Biological Psychiatry最新文献

{"title":"Resveratrol prevents offspring's behavioral impairment associated with immunogenic stress during pregnancy","authors":"Rener Mateus Francisco Duarte ,&nbsp;Erika Renata Ribeiro-Barbosa ,&nbsp;Frederico Rogério Ferreira ,&nbsp;Foued Salmen Espindola ,&nbsp;Vanessa Beatriz Monteiro Galassi Spini","doi":"10.1016/j.pnpbp.2024.111188","DOIUrl":"10.1016/j.pnpbp.2024.111188","url":null,"abstract":"<div><div>Evidence suggests that prenatal maternal immunological stress is associated with an increased risk of neurological and psychiatric disorders in the developing offspring. Protecting the embryo during this critical period of neurodevelopment, when the brain is especially vulnerable, is therefore crucial. Polyphenols, with their antioxidant and anti-inflammatory properties, offer promising therapeutic approaches. This study demonstrated a series of behavioral changes induced by maternal immune activation (MIA) triggered by an antigenic solution derived from the H1N1 virus. These changes include significant differences in anxiety and risk assessment behaviors, increased immobility in the forced swim test, impairments in memory and object recognition, and social deficits resembling autism. The phenolic compound resveratrol (RSV) was evaluated for its in vitro antioxidant capacity and characterized using infrared spectroscopy. Administering RSV from embryonic day 14 (E14) to embrionyc day 19 (E19) during MIA effectively reduced its harmful effects on the offspring. This was evidenced by a significant restoration of social behaviors, memory, and recognition, as well as anxiolytic and antidepressant effects in the adult offspring. These findings contribute to new therapeutic strategies for preventing psychiatric disorders associated with neurodevelopmental stressors.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111188"},"PeriodicalIF":5.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA-specific targets for neuronal plasticity, neurotransmitters, neurotrophic factors, and gut microbes in the pathogenesis and therapeutics of depression","authors":"Cong-Ya Chen,&nbsp;Yu-Fei Wang,&nbsp;Lan Lei,&nbsp;Yi Zhang","doi":"10.1016/j.pnpbp.2024.111186","DOIUrl":"10.1016/j.pnpbp.2024.111186","url":null,"abstract":"<div><div>Depression is of great concern because of the huge burden, and it is impacted by various epigenetic modifications, e.g., histone modification, covalent modifications in DNA, and silencing mechanisms of non-coding protein genes, e.g., microRNAs (miRNAs). MiRNAs are a class of endogenous non-coding RNAs. Alternations in specific miRNAs have been observed both in depressive patients and experimental animals. Also, miRNAs are highly expressed in the central nervous system and can be delivered to different tissues via tissue-specific exosomes. However, the mechanism of miRNAs' involvement in the pathological process of depression is not well understood. Therefore, we summarized and discussed the role of miRNAs in depression. Conclusively, miRNAs are involved in the pathology of depression by causing structural and functional changes in synapses, mediating neuronal regeneration, differentiation, and apoptosis, regulating the gut microbes and the expression of various neurotransmitters and BDNF, and mediating inflammatory and immune responses. Moreover, miRNAs can predict the efficacy of antidepressant medications and explain the mechanism of action of antidepressant drugs and aerobic exercise to prevent and assist in treating depression.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111186"},"PeriodicalIF":5.3,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sigma-1 receptor modulation by fluvoxamine ameliorates valproic acid-induced autistic behavior in rats: Involvement of chronic ER stress modulation, enhanced autophagy and M1/M2 microglia polarization","authors":"Ahmed F. Mohamed ,&nbsp;Mohamad A. El-Gammal ,&nbsp;Mohammed F. EL-Yamany ,&nbsp;Ahmed E. Khodeir","doi":"10.1016/j.pnpbp.2024.111192","DOIUrl":"10.1016/j.pnpbp.2024.111192","url":null,"abstract":"<div><div>Autism spectrum disorder (ASD) is a neurodevelopmental disorder. While, fluvoxamine (FVX) is an antidepressant and widely prescribed to ASD patients, clinical results are inconclusive and the mechanism of FVX in the management of ASD is unclear. This study determined the potential therapeutic impact of FVX, a sigma-1 receptor (S1R) agonist, against the valproic acid (VPA)-induced model of autism. On gestational day 12.5, Wistar pregnant rats were given a single intraperitoneal (i.p.) injection of either VPA (600 mg/kg) or normal saline (10 mL/kg, vehicle-control). Starting on postnatal day (PND) 21 to PND 50, FVX (30 mg/kg, P·O. daily) and NE-100, (S1R) antagonist, (1 mg/kg, i.p. daily) were given to male pups. Behavior tests and histopathological changes were identified at the end of the experiment. In addition, the cerebellum biomarkers of endoplasmic reticulum (ER) stress and autophagy were assessed. Microglial cell polarization to M1 and M2 phenotypes was also assessed. FVX effectively mitigated the histopathological alterations in the cerebellum caused by VPA. FVX enhanced sociability and stereotypic behaviors in addition to its noteworthy impact on autophagy enhancement, ER stress deterioration, and controlling microglial cell polarization. The current investigation confirmed that the S1R agonist, FVX, can lessen behavioral and neurochemical alterations in the VPA-induced rat model of autism.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111192"},"PeriodicalIF":5.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma neurofilament light chain levels are associated with delirium tremens in patients with alcohol use disorder","authors":"Yu-Chi Hou ,&nbsp;Francesco Bavato ,&nbsp;Tung-Hsia Liu ,&nbsp;Hu-Ming Chang ,&nbsp;Hsiang-Wei Kuo ,&nbsp;Shih-Chun Meng ,&nbsp;Yu-Li Liu ,&nbsp;Ming-Chyi Huang","doi":"10.1016/j.pnpbp.2024.111189","DOIUrl":"10.1016/j.pnpbp.2024.111189","url":null,"abstract":"<div><div>Delirium tremens (DT) is the most severe and life-threatening manifestation of alcohol withdrawal. Prompt identification and treatment are crucial in the clinical management of DT, but laboratory markers in this context are still lacking. Neurofilament light chain (NfL) has been proposed as a novel blood marker of neuroaxonal pathology. Therefore, we investigated the association between plasma NfL levels on admission and the occurrence of DT in patients with alcohol use disorder (AUD). NfL levels were measured on admission in 224 patients with AUD undergoing alcohol withdrawal treatment and in 116 healthy individuals. We monitored patients with AUD during the following 2 weeks of hospitalization and categorized them according to the prospective occurrence of DT (<em>n</em> = 25) or not (<em>n</em> = 199). Plasma NfL levels at admission were highest in patients who later developed DT, compared to AUD patients without DT, and healthy individuals (63.1 ± 47.2, 24.0 ± 22.4, 11.8 ± 6.1 pg/mL, respectively, <em>p</em> &lt; 0.001). Receiver operating characteristic analysis revealed that a cut-off NfL level of 27.2 pg/mL could discriminate AUD patients who later developed DT (sensitivity: 80.0 %; specificity: 72.4 %; area under the curve: 0.84, <em>p</em> &lt; 0.001), with an odds ratio of 9.43 (95 % CI 3.26–27.32; <em>p</em> &lt; 0.001) for the risk of developing DT. Our findings suggest that NfL levels at admission may predict DT occurrence in patients with AUD and implicate neuroaxonal pathology in the pathophysiology of DT. Further research is needed to validate these findings and to explore the underlying neurobiological mechanisms.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111189"},"PeriodicalIF":5.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soluble epoxide hydrolase deletion rescues behavioral and synaptic deficits by AMPK-mTOR pathway in autism animals","authors":"Ming-Chia Chu ,&nbsp;Han-Fang Wu ,&nbsp;Chi-Wei Lee ,&nbsp;Chi-Chun Wu ,&nbsp;Hsiang Chi ,&nbsp;Chiung-Yuan Ko ,&nbsp;Yi-Chao Lee ,&nbsp;Chih-Wei Tang ,&nbsp;Po See Chen ,&nbsp;Hui-Ching Lin","doi":"10.1016/j.pnpbp.2024.111190","DOIUrl":"10.1016/j.pnpbp.2024.111190","url":null,"abstract":"<div><div>Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by social defects often accompanied with emotional comorbidities. Aberrations in synaptic function and plasticity are the core feature in the pathophysiology of ASD. Targeting soluble epoxide hydrolase (sEH) has been found to exert protection in a wide-range of pathological conditions. However, the regulation of sEH deficiency on the synaptic deficits of ASD and the underlying mechanisms remain unclear. The valproate (VPA)-treated ASD animal model with genetic sEH knockout was applied in the present study. The results showed that the sEH expression was significantly increased in the prefrontal cortex of VPA-treated animals. Although no effect was found on tail malformation and body weight loss, genetic sEH deletion alleviated social deficits, and fear learning and memory extinction in the VPA-treated mice. After a series of electrophysiological assessments, we found that the beneficial effects of sEH deletion focused on the long-term synaptic plasticity, rather than presynaptic efficiency, in the VPA-treated mice. Furthermore, we observed that the dysregulated AMPK-mTOR pathway was restored under genetic sEH deletion in VPA-treated mice. Taken together, these findings uncovered an important role of sEH deficiency in the synaptic dysfunctions of ASD mediated by AMPK-mTOR pathway, providing a novel therapeutic target for ASD.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111190"},"PeriodicalIF":5.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional connectivity changes in males with nicotine addiction: A triple network model study","authors":"Jieping Sun ,&nbsp;Huiyu Huang ,&nbsp;Jinghan Dang ,&nbsp;Mengzhe Zhang ,&nbsp;Xiaoyu Niu ,&nbsp;Qiuying Tao ,&nbsp;Yimeng Kang ,&nbsp;Longyao Ma ,&nbsp;Bohui Mei ,&nbsp;Weijian Wang ,&nbsp;Shaoqiang Han ,&nbsp;Jingliang Cheng ,&nbsp;Yong Zhang","doi":"10.1016/j.pnpbp.2024.111187","DOIUrl":"10.1016/j.pnpbp.2024.111187","url":null,"abstract":"<div><h3>Background</h3><div>Nicotine addiction (NA) is recognized as a significant neurobehavioral disorder that affects both individuals and society. It is suggested that alterations in functional network connectivity (FNC) within specific brain networks underlie its neurobiological basis.</div></div><div><h3>Methods</h3><div>The default mode network (DMN), executive control network (ECN), and salience network (SN) are identified using data from the Human Connectome Project. The study includes 47 individuals with NA and 35 normal controls (NC), all of whom undergo resting-state fMRI alongside smoking-related clinical assessments. A sliding window analysis is employed to assess connectivity metrics, including static functional network connectivity (FNC), standard deviation (SD), and coefficient of variation (CV), to compare information integration between the groups. Participants with NA are classified based on longitudinal changes in Fagerström Test for Nicotine Dependence (FTND) scores over six years into three categories: addiction tendency (AT), withdrawal tendency (WT), and stable tendency (ST). Correlation analyses are conducted to explore relationships between FNC abnormalities and clinical assessments.</div></div><div><h3>Results</h3><div>Individuals with NA exhibit reduced static FNC (<em>p</em>_FDR = 0.029) between the dorsal DMN and the right ECN, accompanied by increased SD (<em>p</em>_FDR = 0.029) and CV (<em>p</em>_FDR = 0.029). A significant increase in SD (<em>p</em>_FDR = 0.049) is also observed in the dorsal DMN and left ECN. Correlations indicate that the SD of the dorsal DMN and right ECN relates to the pharmacological dimension of the Russell Smoking Reasons Questionnaire (RRSQ) scale (<em>r</em> = 0.416, <em>p</em>_FDR = 0.044), while CV correlates with changes in the FTND over six years (<em>r</em> = −0.391, <em>p</em>_FDR = 0.044) and the pharmacological dimension of the RRSQ scale (<em>r</em> = 0.402, <em>p</em>_FDR = 0.044). Post-hoc subgroup analyses reveal that these FNC intensity changes are present among WT patients (<em>p</em>_FDR &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Alterations in brain network function within the DMN and ECN are suggested to precede behavioral changes in NA. These findings are interpreted as potential neurobiological markers of nicotine addiction.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111187"},"PeriodicalIF":5.3,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural and functional alterations in different types of delusions across schizophrenia spectrum: A systematic review","authors":"Anastasiia N. Dudina ,&nbsp;Alexander S. Tomyshev ,&nbsp;Ekaterina V. Ilina ,&nbsp;Dmitriy V. Romanov ,&nbsp;Irina S. Lebedeva","doi":"10.1016/j.pnpbp.2024.111185","DOIUrl":"10.1016/j.pnpbp.2024.111185","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Despite the high clinical role of delusions as a transnosological psychopathological phenomenon, the number of experimental studies on the different types of delusions across schizophrenia spectrum is still relatively small, and their results are somehow inconsistent. We aimed to understand the current state of knowledge regarding the structural and functional brain alterations in delusions to determine whether particular types of delusions are associated with specific brain changes and to identify common alterations underlying the formation and persistence of delusions regardless of their content.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;For this systematic review, we followed PRISMA guidelines to search in PubMed for English papers published between 1953 and September 30, 2023. The initial inclusion criteria for screening purposes were articles that investigated delusions or subclinical delusional beliefs in schizophrenia spectrum disorders, high clinical or genetic risk for schizophrenia using fMRI, sMRI or/and dwMRI methods. Exclusion criteria during the screening phase were articles that investigated lesion-induced or substance-induced delusions, delusions in Alzheimer's disease and other neurocognitive disorders, single case studies and non-human studies. The publication metadata were uploaded to the web-tool for working on systematic reviews, Rayyan. For each of the studies, a table was filled out with detailed information.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;We found 1752 records, of which 95 full-text documents were reviewed and included in the current paper. Both nonspecific and particular types of delusions were associated with widespread structural and functional alterations. The most prominent areas affected across all types of delusions were the superior temporal cortex (predominantly left language processing areas), anterior cingulate/medial prefrontal cortex and insula. The most reproducible findings in paranoia may be alterations in the functioning of the amygdala and its interactions with other regions. Somatic delusions and delusional infestation were mostly characterized by alterations in the insula and thalamus.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;The data are ambiguous; however, in general the predictive processing framework seems to be the most widely accepted approach to explaining different types of delusions. Aberrant prediction errors signaling during processing of social, self-generated and sensory information may lead to inaccuracies in assessing the intentions of others, self-relevancy of ambiguous stimuli, misattribution of self-generated actions and unusual sensations, which could provoke delusional ideation with persecutory, reference, control and somatic content correspondingly. However, currently available data are still insufficient to draw conclusions about the specific biological mechanisms of predictive coding account of delusions. Thus, further studies exploring more homogeneou","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111185"},"PeriodicalIF":5.3,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared polygenic susceptibility to treatment response in severe affective and psychotic disorders: Evidence from GWAS data sets","authors":"Fernando Facal ,&nbsp;Javier Costas","doi":"10.1016/j.pnpbp.2024.111183","DOIUrl":"10.1016/j.pnpbp.2024.111183","url":null,"abstract":"<div><div>While schizophrenia (SCZ), bipolar disorder (BD) and major depressive disorder (MDD) genetically correlate, the pleiotropy underlying response/resistance to drugs used in these disorders has not been investigated. The aim of this study is to analyze the genetic relationship between treatment-resistant schizophrenia (TRS), response to lithium in BD (respLi) and response to antidepressants in MDD (respAD) using the conditional/conjunctional false discovery rate (cond/conjFDR) methodology, based on the hypothesis that shared mechanisms related to a common psychopathology factor underlie these phenotypes. A cross-trait polygenic enrichment for TRS conditioned on associations with respLi was observed. The conjFDR analysis identified rs11631065 (chr15:66654304) as a shared locus between them. One of the genes at this locus is <em>MAP2K1</em>, previously reported as associated with TRS after conditioning on body mass index genome-wide association study (GWAS). The set of genes at TRS-respLi <em>conjFDR</em> &lt; 0.95 showed enrichment in response to psychotropic drugs in severe mental disorders from GWAS Catalog as well as in neurodevelopment and synaptic pathways. In conclusion, our study constitutes the first evidence of a transdiagnostic genetic signal associated with response to different pharmacological treatments in psychotic and affective disorders. It is necessary to confirm these results when larger GWAS of these phenotypes are available.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111183"},"PeriodicalIF":5.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142539924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duration of aversive memory in zebrafish after a single shock","authors":"Ana Luisa Pires Moreira ,&nbsp;Fabiano Peres Menezes ,&nbsp;Francisco Carlos da Silva Junior ,&nbsp;Ana Carolina Luchiari","doi":"10.1016/j.pnpbp.2024.111182","DOIUrl":"10.1016/j.pnpbp.2024.111182","url":null,"abstract":"<div><div>Studies on memory consolidation and reconsolidation, memory loss, and the associated biochemical mechanisms have garnered interest in the past decades due to knowledge of memory performance-affecting factors such as stress, emotions, sleep, age, several neurological diseases, drugs, and chemical pollutants. Memory research has been using animal models, with increased interest in the zebrafish model. This freshwater fish species shows a wide range of behaviors relevant to memory research such as social behavior, aggression, and predator avoidance; however, few studies have investigated the duration of long-term memory. Hence, we designed an experiment to test memory duration by exposing zebrafish to avoidance conditioning using electroshock as the aversive stimulus. Zebrafish were trained to avoid the black side of a black-and-white tank and subsequently tested for aversive memory at 24 h, 48 h, 72 h, 96 h, 168 h, and 240 h. At the 72 h-interval, another zebrafish group was trained and exposed to MK-801(NMDAr antagonist) and then tested. The fish retained memories of the task and avoided the black side of the tank for up to 7 days. At 10 days post-training, the animals could no longer retrieve the aversive memory. Zebrafish treated with MK-801 did not retrieve memory. Knowledge of memory and of long-term memory duration is crucial for optimizing the zebrafish model for use in research investigating cognitive impairments such as memory loss and its ramifications. Additionally, identifying a long-term aversive memory lasting up to 7 days in zebrafish enables further research into the neuronal changes underlying this persistence. Such in-depth investigation could bring valuable insights into memory mechanisms and facilitate targeted interventions for memory-related conditions.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111182"},"PeriodicalIF":5.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part II: The future","authors":"Antonio M. Persico ,&nbsp;Lisa Asta ,&nbsp;Fethia Chehbani ,&nbsp;Silvestro Mirabelli ,&nbsp;Valeria Parlatini ,&nbsp;Samuele Cortese ,&nbsp;Celso Arango ,&nbsp;Benedetto Vitiello","doi":"10.1016/j.pnpbp.2024.111176","DOIUrl":"10.1016/j.pnpbp.2024.111176","url":null,"abstract":"<div><div>Part I of this systematic review summarized the state-of-the-art of pediatric psychopharmacology for Autism Spectrum Disorder (ASD), a severe and lifelong neurodevelopmental disorder. The purpose of this Part II follow-up article is to provide a systematic overview of the experimental psychopharmacology of ASD. To this aim, we have first identified in the <span><span>Clinicaltrials.gov</span><svg><path></path></svg></span> website all the 157 pharmacological and nutraceutical compounds which have been experimentally tested in children and adolescents with ASD using the randomized placebo-controlled trial (RCT) design. After excluding 24 drugs already presented in Part I, a systematic review spanning each of the remaining 133 compounds was registered on Prospero (ID: CRD42023476555), performed on PubMed (August 8, 2024), and completed with EBSCO, PsycINFO (psychology and psychiatry literature) and the Cochrane Database of Systematic reviews, yielding a total of 115 published RCTs, including 57 trials for 23 pharmacological compounds and 48 trials for 17 nutraceuticals/supplements. Melatonin and oxytocin were not included, because recent systematic reviews have been already published for both these compounds. RCTs of drugs with the strongest foundation in preclinical research, namely arbaclofen, balovaptan and bumetanide have all failed to reach their primary end-points, although efforts to target specific patient subgroups do warrant further investigation. For the vast majority of compounds, including cannabidiol, vasopressin, and probiotics, insufficient evidence of efficacy and safety is available. However, a small subset of compounds, including <em>N</em>-acetylcysteine, folinic acid, <span>l</span>-carnitine, coenzyme Q10, sulforaphane, and metformin may already be considered, with due caution, for clinical use, because there is promising evidence of efficacy and a high safety profile. For several other compounds, such as secretin, efficacy can be confidently excluded, and/or the data discourage undertaking new RCTs. Part I and Part II summarize “drug-based” information, which will be ultimately merged to provide clinicians with a “symptom-based” consensus statement in a conclusive Part III, with the overarching aim to foster evidence-based clinical practices and to organize new strategies for future clinical trials.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111176"},"PeriodicalIF":5.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}